Detalhe da pesquisa
1.
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Gynecol Oncol
; 158(3): 666-672, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32624235
2.
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Ann Oncol
; 28(1): 103-109, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177480
3.
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.
Ann Oncol
; 28(7): 1612-1617, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472235
4.
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
ESMO Open
; 9(5): 103443, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692082
5.
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
Br J Cancer
; 100(4): 601-7, 2009 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19190632
6.
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.
Ann Oncol
; 20(12): 1959-63, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19556321
7.
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.
Gynecol Oncol
; 113(1): 16-20, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19232434
8.
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
J Cancer Res Clin Oncol
; 123(4): 227-31, 1997.
Artigo
em Inglês
| MEDLINE | ID: mdl-9177496
9.
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.
Anticancer Res
; 32(3): 1045-9, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22399630
10.
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.
Ann Oncol
; 15(1): 104-12, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14679128